Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat 
Meta Raises 2026 Capex Outlook Amid AI Spending Surge, Shares Drop After Earnings 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
Alphabet Earnings Surge on AI Growth, Cloud Revenue, and Strong Search Performance 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
IRVINE, Calif., April 27, 2017 -- CombiMatrix Corporation (NASDAQ:CBMX), a family health molecular diagnostics company specializing in DNA-based reproductive health and pediatric testing services, announces that it will release financial results for the three months ended March 31, 2017 after market close on Thursday, May 4, 2017. CombiMatrix management will hold an investment community conference call at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss those results and answer questions.
| Live Call: | U.S.: | (866) 634-2258 |
| International: | (330) 863-3454 | |
| Live Webcast: | http://investor.combimatrix.com/events.cfm The webcast replay will be archived for 30 days | |
| Replay: | U.S.: | (855) 859-2056 |
| International: | (404) 537-3406 | |
| Passcode: | 10856966 | |
| The telephone replay will be available for seven days |
About CombiMatrix Corporation
CombiMatrix Corporation provides best-in-class molecular diagnostic solutions and comprehensive clinical support to foster the highest quality in patient care. CombiMatrix specializes in pre-implantation genetic diagnostics and screening, prenatal diagnosis, miscarriage analysis and pediatric developmental disorders, offering DNA-based testing for the detection of genetic abnormalities beyond what can be identified through traditional methodologies. Our testing focuses on advanced technologies, including single nucleotide polymorphism chromosomal microarray analysis, next-generation sequencing, fluorescent in situ hybridization and high resolution karyotyping. Additional information about CombiMatrix is available at www.combimatrix.com or by calling (800) 710-0624.
Company Contact: Mark McDonough President & CEO, CombiMatrix Corporation (949) 753-0624 Investor Contact: LHA Jody Cain (310) 691-7100 [email protected]
